Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)

King Faisal Specialist Hospital & Research Center

Status: Completed

Conditions: Epithelial Ovarian Cancer

Treatments: Drug: Paclitaxel & Carboplatin; Drug: pegylated liposomal Doxorubicin (CAELYX) & Carboplatin

Study type: Interventional

Funder types: Other

Identifiers

NCT00538603

RAC #2051-062

Details and patient eligibility

About

Multi-national, randomized, phase III, GCIG Intergroup study comparing pegylated liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in patients with epithelial ovarian cancer in late relapse. (CALYPSO)

Enrollment: 8 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with epithelial Ovarian cancer in late relapse

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)